-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncotelic Therapeutics enters USD 178,410 convertible note financing with Pacific Pier Capital II

PUBT·08/04/2026 21:02:00
Listen to the news
Oncotelic Therapeutics enters USD 178,410 convertible note financing with Pacific Pier Capital II
  • On Aug. 3, 2026, Oncotelic entered the 2026 Pacific Pier SPA 2 with Pacific Pier Capital II, LP.
  • Issued the 2026 Pacific Pier Note 2 with gross principal of $178,410; 12% original issue discount; 12% annual interest.
  • Note converts at $0.06 per share or 85% of the lowest traded price over the prior 10 trading days.
  • Matures in one year unless prepaid or accelerated on an event of default; default interest rate is 16%.
  • Also issued 500,000 common shares as commitment shares to Pacific Pier.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035999), on August 04, 2026, and is solely responsible for the information contained therein.